Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Total value of the supplies of FC will be US$ 2.773 million
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Subscribe To Our Newsletter & Stay Updated